Tumor necrosis factor-α inhibitor-related immune disorders.

[1]  Tumay Ak,et al.  Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature , 2022, Clinical Rheumatology.

[2]  A. Iagnocco,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update , 2022, Annals of the Rheumatic Diseases.

[3]  Yi-Ming Chen,et al.  Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus , 2022, Frontiers in Medicine.

[4]  N. Bragazzi,et al.  Th2 IL-4/IL-13 dual blockade with Dupilumab is linked to some Emergent Th17 type Diseases including seronegative arthritis, enthesitis/enthesopathy, but not humoral autoimmune diseases. , 2022, The Journal of investigative dermatology.

[5]  M. Sticherling,et al.  Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases. , 2022, Deutsches Arzteblatt international.

[6]  Mittermayer Barreto Santiago,et al.  Vasculitis induced by biological agents used in rheumatology practice: A systematic review , 2021, Archives of rheumatology.

[7]  G. Espinosa,et al.  Anti-TNF-alpha-induced lupus in patients with non-infectious uveitis , 2021, European journal of ophthalmology.

[8]  S. Bugatti,et al.  Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib. , 2021, Rheumatology.

[9]  F. Maurier,et al.  IgA Vasculitis in Patients with Inflammatory Bowel Disease: new insights into the role of TNF-α blockers. , 2021, Rheumatology.

[10]  P. Kung,et al.  Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study , 2021, Scientific Reports.

[11]  Alyssa S Parpia,et al.  Paradoxical psoriasis in pediatric patients: A systematic review , 2021, Pediatric dermatology.

[12]  J. Stewart,et al.  Late-onset Etanercept-associated Ocular Sarcoidosis with Profound Vision Loss , 2021, Ocular immunology and inflammation.

[13]  J. Guinea-Viniegra,et al.  Expression of microRNA‐21 and TIMP‐3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents , 2021, Journal of cutaneous pathology.

[14]  L. Felipez,et al.  Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease , 2021, Case reports in pediatrics.

[15]  J. Miedema,et al.  Drug-induced sarcoidosis-like reactions , 2021, Current opinion in pulmonary medicine.

[16]  A. Gasbarrini,et al.  Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report , 2021, International journal of environmental research and public health.

[17]  A. Bewley,et al.  Systemic sarcoidosis reactions as a result of tumour necrosis factor‐alpha treatment for patients with psoriasis , 2021, Clinical and experimental dermatology.

[18]  T. Keenan,et al.  Clinical features of tumor necrosis factor-α-inhibitor induced chilblain lupus: A case series , 2021, JAAD case reports.

[19]  J. Galloway,et al.  Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[20]  C. McLouth,et al.  Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis. , 2021, Multiple sclerosis and related disorders.

[21]  F. Wood,et al.  Pyoderma gangrenosum induced by biosimilar adalimumab in a seropositive rheumatoid arthritis patient - a paradoxical effect of adalimumab? , 2021, Rheumatology.

[22]  Rafael F. Martín-García,et al.  Psoriatic Alopecia in a Patient With Crohn Disease: An Uncommon Manifestation of Tumor Necrosis Factor α Inhibitors. , 2021, Cutis.

[23]  Constantina A Bounia,et al.  Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature , 2021, Biologics : targets & therapy.

[24]  C. Sieiro Santos,et al.  Anti-TNF-α-induced lupus syndrome , 2021, Zeitschrift für Rheumatologie.

[25]  S. Şaylısoy,et al.  Aseptic meningitis in rheumatoid arthritis after anti-TNF administration: a case-based literature review , 2021, Rheumatology International.

[26]  M. Lopes,et al.  Adalimumab-induced sarcoidosis-like reaction involving oral cavity in rheumatoid arthritis: a case-based review , 2021, Clinical Rheumatology.

[27]  P. V. van Rheenen,et al.  Case Report: Systemic Small-Vessel Vasculitis in an Adolescent With Active Ulcerative Colitis , 2021, Frontiers in Pediatrics.

[28]  P. Durez,et al.  Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitis , 2021, BMJ Case Reports.

[29]  C. Albanesi,et al.  Experimental Methods for the Immunological Characterization of Paradoxical Psoriasis Reactions Induced by TNF-α Biologics. , 2021, Methods in molecular biology.

[30]  M. Murphy,et al.  Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. , 2020, Journal of the American Academy of Dermatology.

[31]  J. Salem,et al.  Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approach. , 2020, Autoimmunity reviews.

[32]  L. Ottini,et al.  Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers , 2020, International journal of molecular sciences.

[33]  Joel A. Smith,et al.  Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus , 2020, Drugs in R&D.

[34]  G. Antoniou,et al.  Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. , 2020, European journal of gastroenterology & hepatology.

[35]  N. Ishimura,et al.  Intermittent Purpura Development Associated with Leukocytoclastic Vasculitis Induced by Infliximab for Crohn's Disease , 2020, Internal medicine.

[36]  N. Lian,et al.  Tumor necrosis factors‐α inhibition‐induced paradoxical psoriasis: A case series and literature review , 2020, Dermatologic therapy.

[37]  M. Harigai,et al.  Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis , 2020, Modern rheumatology case reports.

[38]  Motohisa Yamamoto,et al.  Drug-induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-α and IL-6 Therapy in a Patient with Rheumatoid Arthritis , 2020, Internal medicine.

[39]  C. Tutunaru,et al.  Granuloma Annulare, a Possible Paradoxical Reaction of the Adalimumab Treatment in a Severe Case of Psoriasis Vulgaris , 2020, Current health sciences journal.

[40]  A. Nowacki,et al.  Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-α inhibitor-induced psoriasis: A case-control study. , 2020, Journal of the American Academy of Dermatology.

[41]  J. Szepietowski,et al.  Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review , 2020, Dermatology and Therapy.

[42]  B. Weinshenker,et al.  Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events , 2020, JAMA neurology.

[43]  C. Pavesio,et al.  A review of ocular adverse events of biological anti-TNF drugs , 2020, Journal of Ophthalmic Inflammation and Infection.

[44]  B. Jelaković,et al.  The Association of TNF-Alpha Inhibitors and Development of IgA Nephropathy in Patients with Rheumatoid Arthritis and Diabetes , 2020, Case reports in nephrology.

[45]  B. Goodman,et al.  Rheumatoid Meningitis: Clinical Characteristics, Diagnostic Evaluation, and Treatment , 2020, The Neurohospitalist.

[46]  G. Choukroun,et al.  Spondyloarthritis-Associated IgA Nephropathy , 2020, Kidney international reports.

[47]  R. Jacobsen,et al.  Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden , 2020, Annals of the Rheumatic Diseases.

[48]  T. Montero-Vílchez,et al.  Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis , 2020, Dermatology.

[49]  J. Schulberg,et al.  Anti-TNF rechallenge after infliximab induced lupus in Crohn's disease: A Practical Teaching Case. , 2020, Gastroenterology.

[50]  S. Billings,et al.  Histological Comparison of TNF-α Inhibitor-Induced Psoriasis and Psoriasis Vulgaris. , 2020, Journal of the American Academy of Dermatology.

[51]  Y. Tsuchida,et al.  A case of granulomatous myositis in a patient with rheumatoid arthritis receiving anti-TNF-α treatment , 2020, Modern rheumatology case reports.

[52]  S. Picardo,et al.  Anti‐TNF‐induced lupus in patients with inflammatory bowel disease , 2019, JGH open : an open access journal of gastroenterology and hepatology.

[53]  S. Bugatti,et al.  Established rheumatoid arthritis. The pathogenic aspects. , 2019, Best practice & research. Clinical rheumatology.

[54]  M. Viguier,et al.  Severe attack of Henoch-Schönlein purpura with neurologic involvement during adalimumab treatment for Crohn's disease. , 2020, Journal of Crohn's & colitis.

[55]  H. Abboud.  Iatrogenic demyelinating disorders: New insights, new culprits , 2019, Multiple sclerosis.

[56]  M. de Bandt.  Anti-TNF-alpha-induced lupus , 2019, Arthritis Research & Therapy.

[57]  Guoli Chen,et al.  Etanercept-associated Nephropathy , 2019, Cureus.

[58]  B. Nørgård,et al.  Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease , 2019, Alimentary pharmacology & therapeutics.

[59]  D. Üsküdar Cansu,et al.  Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data. , 2019, Journal of the National Medical Association.

[60]  B. Carleton,et al.  Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases. , 2019, Seminars in arthritis and rheumatism.

[61]  H. Wajant,et al.  TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages , 2019, Front. Cell Dev. Biol..

[62]  M. Aghdashi,et al.  Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept , 2019, Current rheumatology reviews.

[63]  C. Gordon,et al.  2019 update of the EULAR recommendations for the management of systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[64]  C. Conrad,et al.  [Paradoxical psoriasis induced by anti-TNF - a clinical challenge]. , 2019, Revue medicale suisse.

[65]  L. Arnaud,et al.  Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database , 2019, Annals of the rheumatic diseases.

[66]  S. Zheng,et al.  Differential roles of TNFα-TNFR1 and TNFα-TNFR2 in the differentiation and function of CD4+Foxp3+ induced Treg cells in vitro and in vivo periphery in autoimmune diseases , 2019, Cell Death & Disease.

[67]  C. Conrad,et al.  Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon , 2018, Front. Immunol..

[68]  V. Murugesan,et al.  Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis , 2018, Case reports in gastrointestinal medicine.

[69]  A. Gasbarrini,et al.  Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver , 2018, International journal of molecular sciences.

[70]  S. Magina,et al.  Clinical management of Anti‐TNF‐alpha‐induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review , 2018, International journal of dermatology.

[71]  P. Gillet,et al.  Drug‐induced aseptic meningitis: a mini‐review , 2018, Fundamental & clinical pharmacology.

[72]  S. Zheng,et al.  Role of TNF–TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications , 2018, Front. Immunol..

[73]  M. Dougados,et al.  The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study , 2018, The Journal of Rheumatology.

[74]  E. Frati,et al.  Low Doses of Etanercept Can Be Effective to Maintain Remission in Psoriatic Arthritis Patients , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[75]  M. Croft,et al.  TNF activity and T cells. , 2018, Cytokine.

[76]  Y. Shoenfeld,et al.  Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature , 2018, Clinical Rheumatology.

[77]  L. French,et al.  TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis , 2018, Nature Communications.

[78]  B. Kostov,et al.  Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry) , 2017, Expert opinion on drug safety.

[79]  C. Turesson,et al.  Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors , 2017, The Journal of Rheumatology.

[80]  R. Mader,et al.  Antitumor Necrosis Factor-α Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review , 2017, The Journal of Rheumatology.

[81]  E. Andreadou,et al.  CNS Demyelination with TNF-α Blockers , 2017, Current Neurology and Neuroscience Reports.

[82]  J. Bhawan,et al.  Cutaneous side‐effects of biologics in immune‐mediated disorders: A histopathological perspective , 2017, The Journal of dermatology.

[83]  A. López-Sanromán,et al.  Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. , 2017 .

[84]  E. Linos,et al.  Tumor necrosis factor‐&agr; inhibitor‐induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience , 2017, Journal of the American Academy of Dermatology.

[85]  D. Furst,et al.  Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[86]  José Manuel Gallardo Romero,et al.  Rheumatoid lung nodulosis during anti-TNF therapy. , 2017, Medicina clinica.

[87]  K. Petidis,et al.  Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab , 2017, Rheumatology International.

[88]  A. Kyritsis,et al.  Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis , 2017, Journal of Neurology.

[89]  K. Ohmura,et al.  Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort , 2016, PloS one.

[90]  B. Kısacık,et al.  Three cases of anti-TNF induced myositis and literature review. , 2016, Revista brasileira de reumatologia.

[91]  J. Korzenik,et al.  Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA , 2016, Digestive Diseases and Sciences.

[92]  S. McKarns,et al.  Transmembrane TNF–TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression , 2015, The Journal of Immunology.

[93]  S. Alzabin,et al.  Anti‐tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis , 2015, Clinical and experimental immunology.

[94]  M. Clerici,et al.  Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response , 2015, Journal of Clinical Immunology.

[95]  G. Macedo,et al.  Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases. , 2015, World journal of gastroenterology.

[96]  S. Georgin-lavialle,et al.  Extraarticular Manifestations of Rheumatoid Arthritis in Patients under Anti-tumor Necrosis Factor-α Treatment , 2015, The Journal of Rheumatology.

[97]  Dearbhla M. Kelly,et al.  Adalimumab-induced lupus serositis , 2015, BMJ Case Reports.

[98]  K. Iyama,et al.  Nodules in patients with rheumatoid arthritis and methotrexate treatment , 2015, Modern rheumatology.

[99]  S. Mori.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis , 2015, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[100]  T. Takeuchi,et al.  Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review. , 2015, Internal medicine.

[101]  S. Mathieu,et al.  Acute ocular myositis occurring under etanercept for rheumatoid arthritis. , 2014, Joint, bone, spine : revue du rhumatisme.

[102]  M. Soljak,et al.  Extraarticular Manifestations of Rheumatoid Arthritis Develop in Patients Receiving Anti-Tumor Necrosis Factor-α Treatment: A Retrospective Chart Review from a UK Center , 2014, The Journal of Rheumatology.

[103]  D. Darmochwal-Kolarz,et al.  Antiphospholipid antibodies during 6-month treatment with infliximab: A preliminary report , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[104]  M. Argyropoulou,et al.  Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study , 2014, Arthritis Research & Therapy.

[105]  S. Virupannavar,et al.  Possible Association of Etanercept, Venous Thrombosis, and Induction of Antiphospholipid Syndrome , 2014, Case reports in rheumatology.

[106]  R. Caporali,et al.  Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs , 2014, BioMed research international.

[107]  L. J. Dang,et al.  Drug‐induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis , 2014, The Australasian journal of dermatology.

[108]  C. Massone,et al.  Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis , 2014, Lupus.

[109]  A. Silverman,et al.  Golimumab May Induce Exacerbation of Inflammatory Bowel Disease When It Is Used for the Treatment of Ankylosing Spondylitis: A Case Report With A Review of Literature , 2014, American journal of therapeutics.

[110]  P. Sarzi-Puttini,et al.  Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment? , 2014, Autoimmunity reviews.

[111]  C. Duarte,et al.  A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent? , 2013, Clinical Rheumatology.

[112]  H. Riad,et al.  Hepatitis and Lupus-Like Syndrome during Infliximab Therapy for Psoriasis , 2013, Case Reports in Dermatology.

[113]  E. Andreadou,et al.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature , 2013, Case reports in neurological medicine.

[114]  K. Farkas,et al.  Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody? , 2013, Journal of Crohn's & colitis.

[115]  X. Mariette,et al.  Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. , 2013, Rheumatology.

[116]  A. Griffiths,et al.  Infliximab-Induced Psoriasis and Psoriasiform Skin Lesions in Pediatric Crohn Disease and a Potential Association With IL-23 Receptor Polymorphisms , 2013, Journal of pediatric gastroenterology and nutrition.

[117]  J. Kur,et al.  Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature , 2013, Clinical Rheumatology.

[118]  P. V. Schouwenburg,et al.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis , 2013, Nature Reviews Rheumatology.

[119]  M. Ramos-Casals,et al.  Biologics-induced autoimmune diseases , 2013, Current opinion in rheumatology.

[120]  C. Efe.  Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship? , 2013, Autoimmunity reviews.

[121]  M. G. Braun,et al.  Regression von peripheren und pulmonalen Rheumaknoten unter Rituximab-Therapie , 2013, Zeitschrift für Rheumatologie.

[122]  S. Magina,et al.  Anti-TNF-Alpha Induced Psoriasiform Eruptions with Severe Scalp Involvement and Alopecia: Report of Five Cases and Review of the Literature , 2012, Dermatology.

[123]  J. Berthelot,et al.  Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. , 2012, Joint, bone, spine : revue du rhumatisme.

[124]  O. Sokumbi,et al.  Vasculitis associated with tumor necrosis factor-α inhibitors. , 2012, Mayo Clinic proceedings.

[125]  R. D. de Man,et al.  Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. , 2012, Journal of Crohn's & colitis.

[126]  S. Alzabin,et al.  Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway , 2012, Annals of the rheumatic diseases.

[127]  T. Soukup,et al.  Case 1-2012: ANCA associated glomerulonephritis in combination with IgG4-positive mediastinal mass in a patient with ankylosing spondylitis treated with TNF alpha inhibitors. , 2012, Acta medica.

[128]  L. Qiang,et al.  Levels of Circulating Th17 Cells and Regulatory T Cells in Ankylosing Spondylitis Patients with an Inadequate Response to Anti−TNF-α Therapy , 2012, Journal of Clinical Immunology.

[129]  C. Cañas,et al.  Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab , 2012, Rheumatology International.

[130]  J. Berthelot,et al.  New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. , 2011, Seminars in arthritis and rheumatism.

[131]  X. Bosch,et al.  Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. , 2011, Seminars in arthritis and rheumatism.

[132]  Chi-Chen Lin,et al.  Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy , 2011, Arthritis research & therapy.

[133]  D. Symmons,et al.  Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register , 2011, Annals of the rheumatic diseases.

[134]  Philip R. Cohen,et al.  TNF alpha antagonist‐induced lupus‐like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists , 2011, International journal of dermatology.

[135]  P. Vähäsalo,et al.  Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab , 2011, Scandinavian journal of rheumatology.

[136]  A. Saiz,et al.  Monoclonal antibody therapy-associated neurological disorders , 2011, Nature Reviews Neurology.

[137]  K. Peris,et al.  The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans , 2011, PloS one.

[138]  P. Kiely,et al.  BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. , 2010, Rheumatology.

[139]  V. Werth,et al.  Tumor necrosis factor inhibitor-associated dermatomyositis. , 2010, Archives of dermatology.

[140]  C. Massone,et al.  Dermatomyositis During Adalimumab Therapy for Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[141]  P. Szodoray,et al.  Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis , 2010, Scandinavian journal of rheumatology.

[142]  N. Takayanagi,et al.  [Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis]. , 2010, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

[143]  Takahiko Horiuchi,et al.  Transmembrane TNF-α: structure, function and interaction with anti-TNF agents , 2010, Rheumatology.

[144]  Petros P Sfikakis,et al.  The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. , 2010, Current directions in autoimmunity.

[145]  S. Benoit,et al.  Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. , 2010, Arthritis and rheumatism.

[146]  B. Dijkmans,et al.  Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment , 2010, Arthritis research & therapy.

[147]  M. Grover,et al.  Etanercept and venous thromboembolism: a case series , 2010, Journal of medical case reports.

[148]  S. Suissa,et al.  Demyelinating events in rheumatoid arthritis after drug exposures , 2009, Annals of the rheumatic diseases.

[149]  A. Stoppacciaro,et al.  Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis. , 2010, Clinical and experimental rheumatology.

[150]  Sun-Hee Kim,et al.  Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature , 2011, Rheumatology International.

[151]  K. Ohmura,et al.  Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature , 2010, Clinical Rheumatology.

[152]  M. Davis,et al.  Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. , 2009, Mayo Clinic proceedings.

[153]  S. Lepreux,et al.  Cytokine imbalance with increased production of interferon‐α in psoriasiform eruptions associated with antitumour necrosis factor‐α treatments , 2009, The British journal of dermatology.

[154]  S. Zheng,et al.  Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway1 , 2009, The Journal of Immunology.

[155]  A. Mongey,et al.  Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? , 2009, Lupus.

[156]  S. Alzabin,et al.  Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells , 2008, The Journal of experimental medicine.

[157]  B. Zimmermann,et al.  Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents , 2008 .

[158]  N. Screaton,et al.  Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis. , 2008, Rheumatology.

[159]  T. Barnetche,et al.  Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. , 2008, Clinical and experimental rheumatology.

[160]  J. Lopes,et al.  Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. , 2008, Inflammatory bowel diseases.

[161]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[162]  M. Gattinara,et al.  Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients , 2007, Annals of the rheumatic diseases.

[163]  S. Pillemer,et al.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. , 2007, Arthritis and rheumatism.

[164]  F. Bérard,et al.  Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. , 2007, European journal of dermatology : EJD.

[165]  Frederick W. Fraunfelder,et al.  Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. , 2007, Arthritis and rheumatism.

[166]  P. V. van Riel,et al.  Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. , 2007, The Journal of rheumatology.

[167]  D. M. van der Heijde,et al.  Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. , 2007, Arthritis and rheumatism.

[168]  M. Bandt,et al.  Vasculitides induced by TNFα antagonists: a study in 39 patients in France , 2006 .

[169]  M. Broder,et al.  Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. , 2006, Seminars in arthritis and rheumatism.

[170]  G. Burmester,et al.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[171]  T. Luger,et al.  Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. , 2006, Archives of dermatology.

[172]  B. Flourié,et al.  Infliximab Treatment Does Not Induce Organ‐specific or Nonorgan‐specific Autoantibodies Other than Antinuclear and Anti‐Double‐Stranded DNA Autoantibodies in Crohn's Disease , 2005, Inflammatory bowel diseases.

[173]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis , 2005 .

[174]  D. Baeten,et al.  Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. , 2005, Arthritis and rheumatism.

[175]  S. Ehlers,et al.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. , 2005, Seminars in arthritis and rheumatism.

[176]  X. Mariette,et al.  Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey , 2005, Arthritis research & therapy.

[177]  S. Rantapää-Dahlqvist,et al.  Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα , 2004, Annals of the rheumatic diseases.

[178]  B. Ryffel,et al.  Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. , 2005, Immunity.

[179]  M. Braun,et al.  Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. , 2004, The Journal of rheumatology.

[180]  J. Bienvenu,et al.  Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study , 2004, Arthritis research & therapy.

[181]  J. Guilhou,et al.  Psoriatic lesions induced by antitumour necrosis factor‐α treatment: two cases , 2004, The British journal of dermatology.

[182]  S. Chatterjee.  Severe interstitial pneumonitis associated with infliximab therapy , 2004, Scandinavian journal of rheumatology.

[183]  R. Caporali,et al.  Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment , 2004, Arthritis research & therapy.

[184]  E. Baldissera,et al.  Accumulation of plasma nucleosomes upon treatment with anti‐tumour necrosis factor‐α antibodies , 2004 .

[185]  D. Becker-Capeller,et al.  [Development and/or increase of rheumatoid nodules in RA patients following leflunomide therapy]. , 2004, Zeitschrift fur Rheumatologie.

[186]  N. Martinelli,et al.  Anti-TNFα therapy in rheumatoid arthritis and autoimmunity , 2004, Rheumatology International.

[187]  D. Baeten,et al.  Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? , 2003, Annals of the rheumatic diseases.

[188]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[189]  J. Richert,et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.

[190]  P. Miossec,et al.  Infliximab-induced aseptic meningitis , 2001, The Lancet.

[191]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[192]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[193]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[194]  V. Werth,et al.  Leukocytoclastic vasculitis due to etanercept. , 2000, The Journal of rheumatology.

[195]  C. Bunker,et al.  HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies. , 1999, The Journal of investigative dermatology.

[196]  F. Barkhof,et al.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.